Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Patients affected by COVID-19 should be treated according to the severity of their disease. However, not all key national or international organisations define severity in the same way. This imprecision in severity assessment compromises the validity of some therapeutic recommendations. Using individual patient data would better guide and improve therapeutic recommendations for COVID-19.

Two health care workers in PPE on a ward

WHO's guidelines for the treatment of COVID-19 are based on the combined analyses of published randomised control trials (RCTs), using statistical methods that allow for the comparison of various treatments between studies.

IDDO researchers reviewed 81 studies included in the WHO COVID-19 analysis and compared their severity classifications with those used by another international COVID network. The two were the same in only 35% of trials. Of the RCTs evaluated, 69% were considered by the WHO group to include patients with a range of severities. The distribution of disease severities within these groups usually could not be determined, and data on the duration of illness and/or oxygen saturation values were often missing.

The published literature contains a wide variety of COVID-19 severity threshold criteria, definitions and categories. Many of these are arbitrary and to add to the confusion, during the course of the pandemic some of the definitions were changed. Often, the key measures of severity were not reported at all and when they were, they were frequently incomplete or ambiguous.

This imprecision in severity assessment compromises the validity of some therapeutic recommendations. Crucially, it shows that the extrapolation of “lack of therapeutic benefit” shown in hospitalised severely-ill patients on respiratory support to ambulant, mildly-ill patients should not be done. To address these issues, the researchers recommend using individual patient data (IPD) to guide and improve therapeutic recommendations for COVID-19.

The full story is available on the IDDO website

Read the publication 'Definitions matter: Heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis' on the PLOS website

Similar stories

COPCOV investigators meet, and prepare to submit for publication

On 15-16 Dec, COPCOV investigators from around the world met in Bangkok to review study results and plan next steps. Led by co-PIs Prof Sir Nick White and Dr Will Schilling, and funded by the Wellcome Trust, the MORU-led COPCOV ( Chloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting) is the world’s largest multinational trial of COVID-19 prevention.

Researchers call for antimicrobial resistance surveillance to be improved

The number of studies reporting antimicrobial resistance (AMR) data has increased in Africa, South and South East Asia according to new research in the International Journal of Infectious Diseases.

Are we getting tafenoquine dosing right?

Researchers analysing clinical trial data for the new antimalarial drug tafenoquine find that higher doses are needed to cure reliably vivax malaria infection.

Constant genetic surveillance necessary to keep multidrug-resistant malaria parasite strains in check, study finds

Continually monitoring malaria parasite populations is necessary to prevent outbreaks of previously dormant multidrug-resistant malaria strains, say University of Oxford researchers. Multidrug-resistant malaria parasite strains can rapidly grow or collapse in response to public health policy changes, say the researchers in a study published today in The Lancet.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings

Combating drug-resistant malaria

MORU research has contributed to strategies to eliminate malaria in the Greater Mekong Sub-region, helping to prevent the spread of drug-resistant malaria and improving health provision and outcomes for remote communities.